Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IBDetect

Financiado

Cerrado

Point of Care Diagnostic Test for the Differential Diagnosis of Inflammatory Bow...

Point of Care Diagnostic Test for the Differential Diagnosis of Inflammatory Bowel Disease Inflammatory bowel disease (IBD) is an umbrella term referring to two hard to diagnose chronic intestinal diseases: ulcerative colitis (UC) and Crohn's disease (CD). IBD is a relapsing condition and diagnosis can be missed if test... ver más

31/05/2020

IPDx

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

IPDX DIAGNOSTICS OU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

IPDx

50.00K€ | Lider

AQUATEC PROYECTOS PARA EL SE...

365.11K€ | Participante

FARELL INSTRUMENTS

319.28K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IBD-CHARACTER Inflammatory Bowel Disease CHARACTERization by a multi modal... 8M€ Cerrado

REINFORCE Inflammatory Bowel Disease an EU NZ integrated approach for... 536K€ Cerrado

IMMUNOBIOME Identifying microbiotal triggers of inflammatory bowel disea... 2M€ Cerrado

RTC-2017-6564-1 SISTEMA ANALÍTICO AUTOMATIZADO BASADO EN BIOMARCADORES FECAL... 598K€ Cerrado

MITI 2 Gut Microbiota-Induced Tregs for Inflammatory-Bowel-Disease... 6M€ Cerrado

VIGOR++ Virtual GastrOintestinal tRact 4M€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2019-11-15
Fecha Fin: 2020-05-31

Líder del proyecto

IPDX DIAGNOSTICS OU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Inflammatory bowel disease (IBD) is an umbrella term referring to two hard to diagnose chronic intestinal diseases: ulcerative colitis (UC) and Crohn's disease (CD). IBD is a relapsing condition and diagnosis can be missed if tests are carried out during remission. Thus, the diagnosis of IBD relies on a combination of different tests over a long period. However, for half the patients this results in late diagnosis, a major drawback since often the optimal treatment and management is already affected. Furthermore, IBD diagnosis using current tools (1) can be uncomfortable for patients, (2) carry significant risks including gastrointestinal perforation, and (3) in terms of monetary cost are expensive. Thus, in recent years researchers have been investigating the role of the gut microbiome in IBD, hoping to identify trademark features that could speed up diagnosis and combat the increasing prevalence of IBD in western socities. However, until now the use of this approach has been limited in the field of routine clinical diagnostics due to several limitations. After years of R&D, IPDx has overcome these concerns and introduces IBDetect: the world´s first single test for the differential detection of IBD. It can be used discriminate between the two different types of IBD from a very early, pre-symptomatic stage. All of this can be done in a minimally invasive, cost- and time-effective way with remarkable accuracy. IBDetect can be used to decrease the mean time to diagnosis in UC and CD as well as benefit the optimal treatment and management of these diseases. Our primary target group include gastroenterologists in European hospitals and medical centres in the US. We address the global in vitro diagnostics market in which the IBD-related gastrointestinal diagnostics segment is estimated to reach over €7 billion by 2026. During the Phase 1 study IPDx will conduct a comprehensive feasibility study that includes both technical and commercialisation aspects of the innovation.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores